News Release

Monash study exposes key tactic used by deadly fungus

Peer-Reviewed Publication

Monash University


image: This photo shows from left to right Monash Biomedicine Discovery Institute's Dr Jiyoti Verma, Associate Professor Ana Traven, Dr Thomas Naderer and Dr Tim Tucey. view more 

Credit: Steve Morton, Monash University

A multidisciplinary study by Monash University Biomedicine Discovery Institute (BDI) researchers has revealed that a lethal fungus destroys the immune cell that would ordinarily kill it by stealing its source of nutrients.

Candida albicans is a microscopic fungus commonly found in the human body but which can turn into a dangerous infection in vulnerable hospital patients. These life-threatening infections affect an estimated 400,000 people worldwide annually and have an alarming mortality rate of 40 per cent. C. albicans is one of a handful of fungal species that collectively kill at least 1.5 million people per year.

The study, led by Associate Professor Ana Traven in Monash University's Department of Biochemistry and Molecular Biology, was published today in the high-impact journal Cell Metabolism.

The sugar glucose is important for macrophages, a type of immune cell, to mount an effective attack on disease-causing microbes. As they respond to infection, macrophages undergo a metabolic shift increasing consumption of glucose, and become dependent on it. The fungus competes with the macrophages, rapidly consuming the glucose and causing the macrophages to die.

"The bug turns the immune cell's need to consume glucose against it by depleting this key nutrient, turning the metabolic change in the immune cell into its Achilles' heel," Associate Professor Traven said.

"We did a lot of experiments to prove that this was the case. Now we can see what happens at the interface of immune cells and the microbe. It's a very significant finding," she said.

Associate Professor Traven said that similar research papers looking at immune cell metabolism - a burgeoning field - predominantly studied the host's response to the microbe, not what the microbe was doing.

"That's the significance of our work - we've looked at the whole picture," Associate Professor Traven said.

She said the research was conducted in immune cells and an animal model, and that it remained to be seen how the discovery translated into human disease.

"It's a long road in understanding how you could manipulate metabolism and nutrients to try to help," she said.

Finding alternative treatment strategies was critical in the face of rising concerns over antimicrobial drug resistance, Associate Professor Traven said.

"Although we tend to underestimate their burden, estimates are that deaths from fungal infections are comparable to deaths from tuberculosis and malaria, which are well-recognised global challenges," she said.


Co-first authors on the study were Monash BDI's Drs Timothy Tucey and Jiyoti Verma, with Dr Thomas Naderer as co-senior author with Associate Professor Ana Traven. Dr Traude Beilharz, Department of Biochemistry and Molecular Biology and the Monash Bioinformatics Platform collaborated on using advanced RNA-sequencing technology to probe how the immune cell and the microbe respond to each other. The laboratories of Professor Michael Hickey from Monash University's Centre for Inflammatory Diseases and Associate Professor Rob Wheeler from the University of Maine in the US were also collaborators on this study.

This research was supported by the Australian National Health and Medical Research Council (NHMRC).

Read the full paper in Cell Metabolism titled Glucose homeostasis is important for immune cell viability during Candida challenge and host survival of systemic fungal infection.

DOI: 10.1016/j.cmet.2018.03.019

About the Monash Biomedicine Discovery Institute

Committed to making the discoveries that will relieve the future burden of disease, the newly established Monash Biomedicine Discovery Institute at Monash University brings together more than 120 internationally-renowned research teams. Our researchers are supported by world-class technology and infrastructure, and partner with industry, clinicians and researchers internationally to enhance lives through discovery.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.